Case report: Recurrent lung infections following treatment with pralsetinib for an elderly patient with RET-fusion positive NSCLC

Case report: Recurrent lung infections following treatment with pralsetinib for an elderly patient with RET-fusion positive NSCLC

Patients with RET fusions represent 1-2% of all cases of non-small cell lung cancer (NSCLC), the majority of whom are younger, and are extremely rare in the elderly. As a selective RET inhibitor, pralsetinib has been shown to be efficacious and well-tolerated in patients with RET-fusion NSCLC. Never...

Full description

Bibliographic Details
Main Authors: Li An, Pengzhi Chen, Junfeng Wang, Xuebing Qin, Tingting Liu, Yanhong Gao, Peng Wang, Dong Zhang, Xiangqun Fang, Zhijian Zhang
Format: Article
Language:English
Published: Frontiers Media S.A. 2022-12-01
Series:Frontiers in Oncology
Subjects:
pralsetinib
RET-fusion
lung cancer
cryptococcal pneumonia
pulmonary abscess
Online Access:https://www.frontiersin.org/articles/10.3389/fonc.2022.1024365/full

Similar Items

Similar Items